Date: 2011-01-28
Type of information:
phase: 3
Announcement: recruitment of the first patient
Company: AB Science (France)
Product: masitinib
Action mechanism: tyrosine kinase inhibitor
Disease: secondary acute myeloid leukaemia
Therapeutic area: Cancer Oncology
Country: 60 centres around the world
Trial details:
Latest news: